WINTON GROUP Ltd Lowers Stock Holdings in ADMA Biologics Inc $ADMA

Key Points

• WINTON GROUP Ltd cut its ADMA Biologics position by 82.3% in the second quarter, selling 118,784 shares and retaining 25,600 shares valued at approximately $214,000.
• Several other institutional investors increased their holdings substantially, and hedge funds and other institutions collectively own 75.68% of ADMA’s stock.
• ADMA reported quarterly EPS of $0.16, in line with analyst estimates, while revenue rose 2% year over year to $124.39 million. Analysts maintain a consensus “Moderate Buy” rating with an average price target of $18.67, versus a recent share price of $9.11.

WINTON GROUP Ltd reduced its holdings in shares of ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 82.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 25,600 shares of the biotechnology company's stock after selling 118,784 shares during the period. WINTON GROUP Ltd's holdings in ADMA Biologics were worth $214,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the business. Royal Bank of Canada boosted its position in ADMA Biologics by 448.8% during the 1st quarter. Royal Bank of Canada now owns 929,326 shares of the biotechnology company's stock valued at $8,373,000 after buying an additional 759,984 shares during the period. Bank of America Corp DE increased its position in shares of ADMA Biologics by 107.5% in the first quarter. Bank of America Corp DE now owns 3,997,675 shares of the biotechnology company's stock valued at $36,019,000 after acquiring an additional 2,071,338 shares during the period. Louisiana State Employees Retirement System purchased a new position in shares of ADMA Biologics in the first quarter valued at about $951,000. BNP Paribas Financial Markets raised its stake in shares of ADMA Biologics by 2,188.4% during the fourth quarter. BNP Paribas Financial Markets now owns 1,141,106 shares of the biotechnology company's stock valued at $20,814,000 after acquiring an additional 1,091,241 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd raised its stake in shares of ADMA Biologics by 1,508.1% during the first quarter. Y Intercept Hong Kong Ltd now owns 1,075,422 shares of the biotechnology company's stock valued at $9,690,000 after acquiring an additional 1,008,548 shares during the last quarter. 75.68% of the stock is owned by hedge funds and other institutional investors.

ADMA Biologics Stock Performance

ADMA opened at $9.11 on Friday. The company has a 50 day simple moving average of $9.21 and a two-hundred day simple moving average of $9.84. The company has a debt-to-equity ratio of 0.49, a current ratio of 6.97 and a quick ratio of 3.81. The firm has a market cap of $2.04 billion, a P/E ratio of 13.01 and a beta of 0.78. ADMA Biologics Inc has a 1-year low of $7.21 and a 1-year high of $20.46.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last posted its earnings results on Wednesday, August 5th. The biotechnology company reported $0.16 EPS for the quarter, hitting analysts' consensus estimates of $0.16. ADMA Biologics had a return on equity of 40.17% and a net margin of 32.98%.The company had revenue of $124.39 million for the quarter, compared to the consensus estimate of $125.34 million. During the same period in the previous year, the business earned $0.14 earnings per share. The firm's revenue for the quarter was up 2.0% on a year-over-year basis. Equities analysts forecast that ADMA Biologics Inc will post 0.78 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

ADMA has been the topic of several recent analyst reports. Mizuho cut their price target on shares of ADMA Biologics from $20.00 to $17.00 and set an "outperform" rating on the stock in a report on Wednesday, July 15th. Weiss Ratings reaffirmed a "hold (c)" rating on shares of ADMA Biologics in a research report on Monday. Raymond James Financial assumed coverage on shares of ADMA Biologics in a research report on Wednesday, June 10th. They issued an "outperform" rating and a $21.00 target price for the company. Finally, Zacks Research upgraded shares of ADMA Biologics from a "strong sell" rating to a "hold" rating in a research report on Wednesday, September 2nd. Three research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, ADMA Biologics currently has a consensus rating of "Moderate Buy" and an average price target of $18.67.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company focused on developing, manufacturing and marketing plasma-derived biologic products for patients with compromised or inadequate immune systems. The company's activities include operating plasma collection centers, sourcing human plasma, and producing specialized immunoglobulin therapies.

ADMA's marketed products include ASCENIV, an intravenous immune globulin indicated for the treatment of primary humoral immunodeficiency disease; BIVIGAM, an intravenous immune globulin for primary humoral immunodeficiency; and Nabi-HB, a hepatitis B immune globulin used to provide protection against hepatitis B infection in certain clinical settings.

Want to see what other hedge funds are holding ADMA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ADMA Biologics Inc (NASDAQ:ADMA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.